Navigation Links
Abbott Receives CE Mark Certification

The CE Mark certification has been received by the global healthcare company Abbott towards a new test for detecting the Neissera gonorrhoeae (NG) and Chlamydia trachomatis // (CT) sexually transmitted pathogens. This will enable the company to sell the product in the European Union (EU). The test will be conducted through the Abbott m2000?, which uses real time polymerase chain reaction (PCR) and magnetic particle technology.

Where sexually transmitted diseases are concerned, gonorrhea and chlamydia are the most common, and accurate detection of these diseases can serve to avoid serious illness at a later stage. The European laboratories will be able to get highly reliable test results through the combination of the Abbott m2000 system and the Abbott RealTime? CT/NG assay. The amplified nucleic acid tests can be done on urine samples in a non-invasive manner. Processes like molecular tests, sample preparation and data analysis are automated through the use of the m2000.

As many as 300 million sexually transmitted diseases infections occur across the world annually, according to the World Health Organization (WHO), of which gonorrhea accounts for 55 million and chlamydia accounts for another 85 million. No symptoms are seen in the case of these diseases in 10% of the men and 80% of the women who are infected, even though they are fully capable of infecting others with the disease.

If they are not properly treated, it can result in serious complications like urethritis, sterility, and pelvic inflammatory diseases. Antibiotics are capable of curing both the strains of the disease. Abbott has an alliance with the Celera Diagnostics in Europe through which the test will be made available. Tests are being conducted to detect the hepatitis B virus and HIV/AIDS also through the Abbott m2000 system.
'"/>




Page: 1

Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott to Subsidize Price of HIV Drug
5. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
6. Fifth US Patient Receives Artificial Heart
7. Northfield Labs Receives FDA Comments
8. British MPs Say Prostate Cancer Receives Low Priority in the NHS
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: